Among these products is the novel cPass SARS-CoV-2 Surrogate Virus Neutralization Test Kit which detects the presence of neutralizing antibodies in an hour and does not require live biological materials or biosafety containment for testing.
This is a major advance in understanding the epidemiology of the disease and if individuals have developed neutralizing antibodies that may confer immunity.
The surrogate Virus Neutralization test kit is the result of an exclusive co-development agreement between Dr. Linfa Wang at Duke –NUS Medical School in Singapore, GenScript Biotech Corp., and the Diagnostics Development Hub at Singapore's Agency for Science Technology and Research (A*STAR).
Dr. Linfa Wang, a virologist, epidemiologist, and director of the Emerging Infectious Disease program at Duke-NUS Medical School is one of the world's leading experts on emerging zoonotic viruses. Dr. Wang serves on multiple World Health Organization committees focused on COVID-19 and is the principal investigator of the collaboration.
GenScript went through the proof of concept research, product design, development, and optimization, working with Dr. Wang and the A*STAR team. GenScript now plays a central role in the commercialization process using its global network and manufacturing capabilities.
Together with the other CE-IVD tests GenScript offers including qRT-PCR detection kits and IgG and IgM serological testing kits, one can monitor the complete infection history of a person, from initial infection through the different stages of infection to the point of monitoring neutralizing antibodies as an indicator of future immunity against the virus.
GenScript is a global biotechnology group providing gene, peptide, protein, CRISPR, and antibodies to scientists in more than 100 countries.
Since its founding in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early-stage pharmaceutical development.
With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial